Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD.
about
Adenosine A 2A receptor antagonist istradefylline for levodopa-induced complications in Parkinson's diseaseAdenosine receptors as therapeutic targetsAvailable and emerging treatments for Parkinson's disease: a reviewThe A(2A)-adenosine receptor: a GPCR with unique features?Adenosine A2A receptors in ventral striatum, hypothalamus and nociceptive circuitry implications for drug addiction, sleep and painHighlights on the development of A(2A) adenosine receptor agonists and antagonistsAdenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson diseaseAdenosine A(2A) Receptor Antagonists and Parkinson's DiseaseMutation in ADORA1 identified as likely cause of early-onset parkinsonism and cognitive dysfunction.G protein-coupled receptor heterocomplexes in neuropsychiatric disorders.Caffeine and progression of Parkinson diseaseMethylxanthines, seizures, and excitotoxicity.A randomized, double-blind, placebo-controlled study to investigate the safety, tolerability, and pharmacokinetics of single enantiomer (+)-mefloquine compared with racemic mefloquine in healthy personsAdenosine A2A receptor antagonist istradefylline 20 versus 40 mg/day as augmentation for Parkinson's disease: a meta-analysis.Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces "off" time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005).Preclinical jockeying on the translational track of adenosine A2A receptors.Functional models of Parkinson's disease: a valuable tool in the development of novel therapies.Pathophysiological roles for purines: adenosine, caffeine and urate.Past, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson's disease.Plasticity of purine release during cerebral ischemia: clinical implications?Asian perspectives on the recognition and management of levodopa 'wearing-off' in Parkinson's disease.Adenosine A2A receptor in the monkey basal ganglia: ultrastructural localization and colocalization with the metabotropic glutamate receptor 5 in the striatum.Purinergic-receptor oligomerization: implications for neural functions in the central nervous system.A(2A) Receptor Antagonism and Dyskinesia in Parkinson's DiseaseOther pharmacological treatments for motor complications and dyskinesias.Novel pharmacological strategies for motor complications in Parkinson's disease.New therapeutic approaches to Parkinson's disease including neural transplants.The adenosine kinase hypothesis of epileptogenesisTranslation of nondopaminergic treatments for levodopa-induced dyskinesia from MPTP-lesioned nonhuman primates to phase IIa clinical studies: keys to success and roads to failure.Levodopa, motor fluctuations and dyskinesia in Parkinson's disease.Emerging drugs for Parkinson's disease.Novel pharmacological targets for the treatment of Parkinson's disease.Drug Insight: new drugs in development for Parkinson's disease.Intramembrane receptor-receptor interactions: a novel principle in molecular medicine.Adenosine A(2A) receptors in Parkinson's disease treatment.Pharmacological treatment of Parkinson's disease: life beyond dopamine D2/D3 receptors?Current status of symptomatic medical therapy in Parkinson's diseasePreventing and controlling dyskinesia in Parkinson's disease--a view of current knowledge and future opportunities.Targets for neuroprotection in Parkinson's diseaseAdenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson's disease.
P2860
Q24201502-DBC2584D-56BF-4302-A7B3-A25783568DD9Q24632095-E3ADED25-9F44-4CE0-A4BF-7C7E23D98029Q24633444-FDA1C137-3BD7-42FE-AD91-758CC1052AECQ24653743-F5E4A879-107A-4EF1-8B21-F9D4B94FCF5FQ24676705-F27294C6-1F56-47DE-B315-854C4B4F89DFQ28279556-51ABBAA0-7298-4C4D-80E6-821567274E76Q29346490-05916544-EC2B-4AAA-A7D2-0185EEC750B5Q29346492-574742C8-C77D-4238-A594-2DAAAF4A34D1Q29347530-848D8990-6296-4831-827B-80723B06D7DAQ30385233-CFE3B188-7060-4A02-A16A-E09D7166BB7CQ30432945-2E8C21AE-DB40-4396-B7D5-FB2D20578CD0Q34154555-6C19D010-9575-46E5-8760-5BEE1095F69AQ34341756-C654E8A0-E1A9-46D6-AEB4-B6E70DC87C02Q34414817-C03FAC0A-339F-4597-A21C-34CDD102E055Q34756419-DCA8678B-F6EF-4F1C-8B71-7780418B4FB9Q34777609-C94635D2-C496-4C41-8AEB-0057E7D0F37EQ34916732-55251A26-5F57-408C-AEBE-9AB8DAEC1E19Q35008049-9E8B6BC1-07BE-4D6D-9A26-371377695B48Q35489240-8B12C65C-D397-418E-8858-8A50019BC4A9Q35644634-3D89CBB9-B4F4-41B9-AF59-C7E6DF29ABE0Q35781883-A3420F5D-88BC-4BB2-9D31-7996C7BF63EDQ35917127-EB44551B-E8D0-402A-AE43-97275EB88E0CQ35950883-61EEC2F2-5209-410C-B72E-0178B7E3AE5AQ36057652-BC2444B0-11C4-4A7C-94CA-6D4E31F11F11Q36094528-6F885BE9-BDAC-4EB3-A604-B3DAA49C05BFQ36120761-8CE152EE-DFB5-4E9B-AA40-296E2B0B001DQ36225073-EB9C63D6-D76B-4400-A53C-376294EBFEFEQ36515651-4058AD70-5096-4E78-B437-1115E1D51A1EQ36549794-7F249C1A-830D-422D-A32F-5FCC304A91F8Q36573882-B071BCE4-F6A7-47D0-A02C-D72CE7509BDFQ36580572-79C1D125-454D-4294-8DF8-79639452924EQ36610996-FAF951AF-C814-4B78-9038-DA6DB64C0AC0Q36631654-C1C8CBA3-24E6-4075-B966-D30DCAF6E199Q36635157-39E8EF2E-093E-48A4-8369-5EBD7489948AQ36973390-B5852B66-9603-46F9-9120-58A538AC5344Q37077360-AF4D235F-7C05-4F32-A9D7-60598C7CDEABQ37131229-523EF0E0-F1B7-4959-A835-F06060F5E347Q37264464-81F5C2D1-2BAF-4DE1-94AA-FFDB87FE46D1Q37302453-4E3BCF87-FFA7-45F3-8D9E-6FF126AC446AQ37348458-0414394A-214E-4287-B7E5-487149A129AE
P2860
Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Randomized trial of the adenosine A
@nl
Randomized trial of the adenos ...... istradefylline in advanced PD.
@en
type
label
Randomized trial of the adenosine A
@nl
Randomized trial of the adenos ...... istradefylline in advanced PD.
@en
prefLabel
Randomized trial of the adenosine A
@nl
Randomized trial of the adenos ...... istradefylline in advanced PD.
@en
P2093
P1433
P1476
Randomized trial of the adenos ...... istradefylline in advanced PD.
@en
P2093
Daniel D Truong
Istradefylline US-001 Study Group
Jean P Hubble
P304
P356
10.1212/01.WNL.0000081227.84197.0B
P407
P577
2003-08-01T00:00:00Z